account_id none on file
legal_name Rein Therapeutics, Inc.
ticker RNTX
cik 1420565
domain yahoo.com
linkedin_company_url https://www.linkedin.com/company/yahoo
entry_point_account_id none on file
name Rein Therapeutics Inc.
exchange Nasdaq
sector Health Care
hq Austin, TX, United States
sector index/company/sector/health-care/
calls 0 filings 4 executives 0 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses also include legal fees relating to patent and corporate matters; legal and other professional fees relating to our strategic process; other insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
filing / Aug 14, 2026 / receipt
If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve cash.
filing / Aug 14, 2026 / receipt
Cunningham has served as our Interim Chief Financial Officer since May 2024. Since September 2020, Mr. Cunningham has served as chief financial officer consultant at Danforth Advisors, LLC, a national consulting firm providing financial, accounting and reporting services to the life science industry.
filing / Jun 8, 2026 / receipt
Cunningham was appointed as our Interim Chief Financial Officer, effective as of May 16, 2024. Narrative Disclosure to Summary Compensation Table We review compensation for our executive officers annually.
filing / Jun 8, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled |
changes
| 2018-05-16 | President and Chief Executive Officer, departed | sec_8k |
| 2018-03-19 | Chairman, departed | sec_8k |
mcp_package_hint
slug rein-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$